Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Livmoniplimab + Budigalimab in Advanced Hepatocellular Carcinoma
NCT06487559Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of livmoniplimab in hepatocellular carcinoma (HCC) (2 cohorts), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants With Adverse Events, Number of Participants with Dose-Limiting Toxicities and 2 more. Started Sep 2024; status: terminated.
02
Drugs
livmoniplimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06487559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06487559.